Akari Therapeutics PLC (NASDAQ:AKTX) — Stock Price
Akari Therapeutics PLC (NASDAQ:AKTX) is currently trading at $7.53 USD, up 7.57% today. Over the past 52 weeks, shares have ranged between $0.12 and $22.05. This page tracks Akari Therapeutics PLC's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see AKTX stock market capitalisation.
Akari Therapeutics PLC (AKTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Akari Therapeutics PLC's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Akari Therapeutics PLC Income Statement — Revenue, Profit & Earnings by Year
Akari Therapeutics PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | $14.00K | $4.00K | $3.71K | $4.13K |
| Gross Profit | — | $-14.00K | $-4.00K | $-3.71K | $-4.13K |
| Research & Development | $2.81 Million | $6.98 Million | $8.02 Million | $9.56 Million | $9.13 Million |
| SG&A | $9.28 Million | $9.66 Million | $11.36 Million | $13.53 Million | $8.08 Million |
| Total Operating Expenses | $17.27 Million | $21.64 Million | $16.81 Million | $23.09 Million | $17.21 Million |
| Operating Income | $-17.27 Million | $-21.64 Million | $-16.81 Million | $-23.09 Million | $-17.21 Million |
| EBITDA | $-17.35 Million | $-19.53 Million | $-16.80 Million | $-23.08 Million | $-17.21 Million |
| EBIT | — | $-19.55 Million | $-16.81 Million | $-23.09 Million | $-17.21 Million |
| Interest Expense | $949.00K | $244.00K | $0.00 | $5.34 Million | $210.10K |
| Income Before Tax | $-18.30 Million | $-19.79 Million | $-10.01 Million | $-17.75 Million | $-17.42 Million |
| Income Tax Expense | $-1.00 Million | — | — | $-10.78 Million | $182.62K |
| Net Income | $-17.30 Million | $-19.79 Million | $-10.01 Million | $-17.75 Million | $-17.42 Million |
Akari Therapeutics PLC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Akari Therapeutics PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $47.89 Million | $50.56 Million | $4.36 Million | $13.83 Million | $11.65 Million |
| Total Current Assets | $5.46 Million | $2.95 Million | $4.34 Million | $13.81 Million | $11.63 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | $201.00K | — | $2.95 Million | — |
| Inventory | — | — | — | $-2.49 Million | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | $8.43 Million | $8.43 Million | — | — | — |
| Total Liabilities | $19.56 Million | $28.33 Million | $4.58 Million | $12.04 Million | $6.09 Million |
| Total Current Liabilities | $12.35 Million | $19.91 Million | $4.58 Million | $12.04 Million | $6.09 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-4.45 Million | $661.00K | $-3.85 Million | $-13.25 Million | $-9.36 Million |
| Total Stockholder Equity | $28.33 Million | $22.23 Million | $-229.00K | $1.79 Million | $5.55 Million |
| Retained Earnings | $-264.55 Million | $-247.25 Million | $-227.46 Million | $-217.45 Million | $-199.71 Million |
Akari Therapeutics PLC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Akari Therapeutics PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-10.57 Million | $-12.55 Million | $-16.43 Million | $-21.50 Million | $-18.85 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-10.57 Million | $-12.55 Million | $-16.43 Million | $-21.50 Million | $-18.85 Million |
| Investing Cash Flow | — | $382.00K | — | — | — |
| Financing Cash Flow | $13.17 Million | $10.99 Million | $7.02 Million | $25.29 Million | $14.29 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $2.89 Million | $2.25 Million | $1.15 Million | $735.00K | $314.65K |
| Depreciation | $0.00 | $14.00K | $4.00K | $4.00K | $4.13K |
| Change in Cash | $2.60 Million | $-1.19 Million | $-9.40 Million | $3.89 Million | $-4.69 Million |
Akari Therapeutics PLC Earnings History — EPS Actual vs. Analyst Estimates
Track Akari Therapeutics PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | — | -2.40 | — |
| Nov 13, 2025 | -0.20 | -0.11 | -81.82% |
| Aug 13, 2025 | -0.06 | -0.11 | +45.45% |
| Apr 15, 2025 | -0.19 | -1.00 | +81.00% |
| Dec 06, 2024 | -9.50 | — | — |
| Sep 30, 2024 | -0.80 | — | — |
| May 15, 2024 | -0.83 | — | — |
| Oct 12, 2023 | 0.00 | -0.60 | +100.00% |